Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 3214

1.

Application of molecular targeted therapies in the treatment of head and neck squamous cell carcinoma.

Kozakiewicz P, Grzybowska-Szatkowska L.

Oncol Lett. 2018 May;15(5):7497-7505. doi: 10.3892/ol.2018.8300. Epub 2018 Mar 20. Review.

2.

Acquired EGFR T790M Mutation After Relapse Following EGFR-TKI Therapy: A Population-based Multi-institutional Study.

Kaburagi T, Kiyoshima M, Nawa T, Ichimura H, Saito T, Hayashihara K, Yamada H, Satoh H, Endo T, Inage Y, Saito K, Inagaki M, Hizawa N, Sato Y, Ishikawa H, Sakai M, Kamiyama K, Kikuchi N, Nakamura H, Furukawa K, Kodama T, Yamashita T, Nomura A, Yoshida S.

Anticancer Res. 2018 May;38(5):3145-3150.

PMID:
29715155
3.

Feasibility Study of Sequentially Alternating EGFR-TKIs and Chemotherapy for Patients with Non-small Cell Lung Cancer.

Takemura Y, Chihara Y, Morimoto Y, Tanimura K, Imabayashi T, Seko Y, Kaneko Y, Date K, Ueda M, Arimoto T, Iwasaki Y, Takayama K.

Anticancer Res. 2018 Apr;38(4):2385-2390.

PMID:
29599365
4.

Design, synthesis and anticancer evaluation of novel spirobenzo[h]chromene and spirochromane derivatives with dual EGFR and B-RAF inhibitory activities.

Abdelatef SA, El-Saadi MT, Amin NH, Abdelazeem AH, Omar HA, Abdellatif KRA.

Eur J Med Chem. 2018 Apr 25;150:567-578. doi: 10.1016/j.ejmech.2018.03.001. Epub 2018 Mar 5.

PMID:
29549841
5.

p16(INK4a) status and survival benefit of EGFR inhibitors in head and neck squamous cell cancer: A systematic review and meta-analysis.

Su Y, Cui J, Xu D, Wang M, Xu T, Tian H, Han F.

Crit Rev Oncol Hematol. 2018 Apr;124:11-20. doi: 10.1016/j.critrevonc.2018.02.006. Epub 2018 Feb 7. Review.

PMID:
29548481
6.
7.

Recurrent Spindle Cell Carcinoma Shows Features of Mesenchymal Stem Cells.

Ouchi T, Morikawa S, Shibata S, Takahashi M, Yoshikawa M, Soma T, Miyashita H, Muraoka W, Kameyama K, Kawana H, Arima Y, Saya H, Okano H, Nakagawa T, Asoda S.

J Dent Res. 2018 Feb 1:22034518759278. doi: 10.1177/0022034518759278. [Epub ahead of print]

PMID:
29494307
8.

Skin Rash Can Be a Useful Marker for Afatinib Efficacy.

Nasu S, Suzuki H, Shiroyama T, Tanaka A, Iwata K, Ryota N, Ueda Y, Takata SO, Masuhiro K, Morita S, Morishita N, Okamoto N, Hirashima T.

Anticancer Res. 2018 Mar;38(3):1783-1788.

PMID:
29491117
9.

Discovery of 2,4,6-trisubstitued pyrido[3,4-d]pyrimidine derivatives as new EGFR-TKIs.

Zhang H, Wang J, Shen Y, Wang HY, Duan WM, Zhao HY, Hei YY, Xin M, Cao YX, Zhang SQ.

Eur J Med Chem. 2018 Mar 25;148:221-237. doi: 10.1016/j.ejmech.2018.02.051. Epub 2018 Feb 16.

PMID:
29466773
10.

EGFR-PI3K-PDK1 pathway regulates YAP signaling in hepatocellular carcinoma: the mechanism and its implications in targeted therapy.

Xia H, Dai X, Yu H, Zhou S, Fan Z, Wei G, Tang Q, Gong Q, Bi F.

Cell Death Dis. 2018 Feb 15;9(3):269. doi: 10.1038/s41419-018-0302-x.

11.

MicroRNA-1 inhibits tumorigenicity of esophageal squamous cell carcinoma and enhances sensitivity to gefitinib.

Yu Q, Liu Y, Wen C, Zhao Y, Jin S, Hu Y, Wang F, Chen L, Zhang B, Wang W, Zhu Q, Guo R.

Oncol Lett. 2018 Jan;15(1):963-971. doi: 10.3892/ol.2017.7378. Epub 2017 Nov 9.

12.

Intratumoral heterogeneity characterized by pretreatment PET in non-small cell lung cancer patients predicts progression-free survival on EGFR tyrosine kinase inhibitor.

Park S, Ha S, Lee SH, Paeng JC, Keam B, Kim TM, Kim DW, Heo DS.

PLoS One. 2018 Jan 31;13(1):e0189766. doi: 10.1371/journal.pone.0189766. eCollection 2018.

13.

Topical Sunitinib ointment alleviates Psoriasis-like inflammation by inhibiting the proliferation and apoptosis of keratinocytes.

Kuang YH, Lu Y, Liu YK, Liao LQ, Zhou XC, Qin QS, Jia XK, Wu LS, Zhu W, Chen X.

Eur J Pharmacol. 2018 Apr 5;824:57-63. doi: 10.1016/j.ejphar.2018.01.048. Epub 2018 Jan 31.

PMID:
29382533
14.

Osimertinib in patients with epidermal growth factor receptor T790M advanced non-small cell lung cancer selected using cytology samples.

Kiura K, Yoh K, Katakami N, Nogami N, Kasahara K, Takahashi T, Okamoto I, Cantarini M, Hodge R, Uchida H.

Cancer Sci. 2018 Apr;109(4):1177-1184. doi: 10.1111/cas.13511. Epub 2018 Feb 27.

15.

Antitumor effects of histone deacetylase inhibitor suberoylanilide hydroxamic acid in epidermal growth factor receptor-mutant non-small-cell lung cancer lines in vitro and in vivo.

Wei Y, Zhou F, Lin Z, Shi L, Huang A, Liu T, Yu D, Wu G.

Anticancer Drugs. 2018 Mar;29(3):262-270. doi: 10.1097/CAD.0000000000000597.

PMID:
29356692
16.

Comparison of EMT mediated tyrosine kinase inhibitor resistance in NSCLC.

Iderzorig T, Kellen J, Osude C, Singh S, Woodman JA, Garcia C, Puri N.

Biochem Biophys Res Commun. 2018 Feb 5;496(2):770-777. doi: 10.1016/j.bbrc.2018.01.069. Epub 2018 Jan 11.

PMID:
29337056
17.

Erlotinib for coexisting typical bronchial carcinoid and advanced lung adenocarcinoma: does the epidermal growth factor receptor mutation status matter?

Drpa G, Sreter KB, Manojlovic S, Kukulj S.

Anticancer Drugs. 2018 Mar;29(3):281-285. doi: 10.1097/CAD.0000000000000587.

PMID:
29280916
18.

Detection of Rare Mutations in EGFR-ARMS-PCR-Negative Lung Adenocarcinoma by Sanger Sequencing.

Liang C, Wu Z, Gan X, Liu Y, You Y, Liu C, Zhou C, Liang Y, Mo H, Chen AM, Zhang J.

Yonsei Med J. 2018 Jan;59(1):13-19. doi: 10.3349/ymj.2018.59.1.13.

19.

Efficacy of targeted therapy for advanced renal cell carcinoma: a systematic review and meta-analysis of randomized controlled trials.

Wei C, Wang S, Ye Z, Chen Z.

Int Braz J Urol. 2018 Mar-Apr;44(2):219-237. doi: 10.1590/S1677-5538.IBJU.2017.0315. Review.

20.

Durable response to osimertinib in EGFR mutated T790M wildtype non-small cell lung cancer with leptomeningeal metastases: A case report.

Chalmers A, Jensen L, Akerley W.

Lung Cancer. 2017 Dec;114:68-69. doi: 10.1016/j.lungcan.2017.10.009. Epub 2017 Oct 26.

PMID:
29173769

Supplemental Content

Loading ...
Support Center